Literature DB >> 6292145

Compensation techniques in NIRS proton beam radiotherapy.

A Akanuma, H Majima, S Furukawa, R Okamoto, Y K Nakamura, H Tsunemoto, S Morita, T Arai, A Kurisu, T Hiraoka, K Kawachi, T Kanai.   

Abstract

Proton beam has the dose distribution advantage in radiation therapy, although it has little advantage in biological effects. One of the best advantages is its sharp fall off of dose after the peak. With proton beam, therefore, the dose can be given just to cover a target volume and potentially no dose is delivered thereafter in the beam direction. To utilize this advantage, bolus techniques in conjunction with CT scanning are employed in NIRS proton beam radiation therapy planning. A patient receives CT scanning first so that the target volume can be clearly marked and the radiation direction and fixation method can be determined. At the same time bolus dimensions are calculated. The bolus frames are made with dental paraffin sheets according to the dimensions. The paraffin frame is replaced with dental resin. Alginate (a dental impression material with favorable physical density and skin surface contact) is now employed for the bolus material. With fixation device and bolus on, which are constructed individually, the patient receives CT scanning again prior to a proton beam treatment in order to prove the devices are suitable. Alginate has to be poured into the frame right before each treatments. Further investigations are required to find better bolus materials and easier construction methods.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6292145     DOI: 10.1016/0360-3016(82)90628-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  1 in total

1.  Comparison of human chordoma cell-kill for 290 MeV/n carbon ions versus 70 MeV protons in vitro.

Authors:  Hiroshi Fujisawa; Paula C Genik; Hisashi Kitamura; Akira Fujimori; Mitsuru Uesaka; Takamitsu A Kato
Journal:  Radiat Oncol       Date:  2013-04-15       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.